Recommendations and treatment strategies for the management of acute ischemic stroke

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 7, 2008, Pages 1071-1085

  Segura, Tomás ^a,b   Calleja, Sergio ^c   Jordan, Joaquin ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^b UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Clinical trial; Ischemia; Neuroprotection; Stroke management; Thrombolysis

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; [1,2,3,4 TETRAHYDRO 7 (1H IMIDAZOL 1 YL) 6 NITRO 2,3 DIOXO 1 QUINOXALINYL]ACETIC ACID; ABCIXIMAB; ACETYLSALICYLIC ACID; ALBUMIN; ALTEPLASE; AMINO ACID RECEPTOR BLOCKING AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; ARUNDIC ACID; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; CITICOLINE; CYCLOSPORIN A; GLUTAMATE RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAGNESIUM SULFATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PARACETAMOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO; SIMVASTATIN; SODIUM CHANNEL BLOCKING AGENT; UNINDEXED DRUG; VITAMIN; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; NEUROPROTECTIVE AGENT; PLASMINOGEN ACTIVATOR;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; APOPTOSIS; BLEEDING; BLOOD CLOT LYSIS; BODY POSITION; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CALCIUM CELL LEVEL; CELL THERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SOLUBILITY; DRUG TARGETING; FIBRINOLYTIC THERAPY; GLYCEMIC CONTROL; HUMAN; HYPOTENSION; INDUCED HYPOTHERMIA; LOW DRUG DOSE; LUNG EDEMA; MONOTHERAPY; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN TISSUE LEVEL; PATHOPHYSIOLOGY; PERCUTANEOUS THROMBECTOMY; REPERFUSION; REVIEW; SEDATION; SIDE EFFECT; STROKE UNIT; SYMPTOMATOLOGY; ULTRASOUND THERAPY; UNSPECIFIED SIDE EFFECT; ANIMAL; DRUG ANTAGONISM; HOSPITAL SUBDIVISIONS AND COMPONENTS; METHODOLOGY; PATIENT SELECTION; STROKE;

ANIMALS; FIBRINOLYTIC AGENTS; HOSPITAL UNITS; HUMANS; NEUROPROTECTIVE AGENTS; PATIENT SELECTION; PLASMINOGEN ACTIVATORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STROKE; THROMBOLYTIC THERAPY;

EID: 43049183344     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.7.1071     Document Type: Review

References (97)

1. Jones TH, Morawetz RB, Crowell RM. et al. Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg 1981;54:773-82
2. Choi DW, Rotman SM. The role of glutamare neurotoxicity in hypoxic-ischemic neuronal death. Ann Rev Neurosci 1990;13:171-82
3. Muir KW, Less KR. Excitatory amino acid antagonists for acute stroke. Cochrane Database Syst Rev 2003;3:CD001244
4. Wahlgren NG, Bornhov S, Sharma A, et al. for the CLASS Study Group. The Clometiazole Acute Stroke Study (CLASS):efficacy results in 545 patients classified as total anterior circulation syndrome (TACS). J Stroke Cerebrovasc Dis 1999;8:1-10
5. Muir KW, Lees KR, Ford I, Davis S. Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. lancet 2004;363:439-45
6. Saver JL, Kidwell C, Eckstein M, Starkman S. For the FAST-MAG Pilot Trial Investigators. Prehospital neuroprotective therapy for acute stroke. results of the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) pilot trial. Stroke 2004;35:e106-8
7. Diener HC, Hacke W, Hennerici M, et al. Lubezole International Study Group. Lubezole in acute ischemic stroke: a double-blind, placebo-controlled Phase II trial. Stroke 1996;27:76-81
8. Muir KW, Holzapfel L, Lees KR. Phase II clinical trial of sipatrigine (619C89) by continuous infusion in acute stroke. Cerebrovasc Dis 2000;10:431-6
9. Bath PM, Iddenden & Bath FJ, Orgogozo JM. Tirilazad International Steering Committee. Tirilazad for acute ischemic stroke. Cochrane Database Syst Rev 2001;4:CD002087
10. Yamaguchi T, Sano K, Takakura Y. et al. Ebselen Study Group. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Stroke 1998;29:12-7
11. Lees KR, Zivin JA, Ashwood T, et al. Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 fbr acute ischemic stroke. N Engl J Med 2006;354:588-600
12. Shuaib A, Lees KR, Lyden P, et al. SAINT II trial investigators. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007;357:562-71
13. Davalos A. Castillo J, Alvarez-Sabin J, et al. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke 2002;33:2850-7
14. Gomez-Lazaro M, Fernandez-Gomez FJ, Jordan J. p53: twenty five years understanding the mechanism of genome protection. J Physiol Biochem 2004;60:287-307
15. Jordan J, Galindo MF, Gonzalez-Garcia C, Cena V. Role and regulation of p53 in despolarization-induced neuronal death. Neuroscience 2003;122(3):707-15
16. Luo Y, Yin W, Signore AP, et al. Nearoprotections against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem 2006;97:435-48
17. Jordan J, Cena V, Prehn JH. Mitochondrial control of neuron death and its role in ncurodegenerative disorders. J Physiol Biochem 2003;59:129-41
18. Gomez-Lazaro M, Galindo MF, Melero-Fernandez de Mera RM, et al. Reactive oxygen species and p38 mitogen-activated protein kinase activate Bax to induce mitochondrial cytochrome c realease and apoptosis in response to malonate. Mol Pharmacol 2007;71:736-43
19. Boushey JC, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57
20. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vimmin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-75
21. Pettigrew LC, Kassner SE, Albers GW, et al. Arundic Acid (ONO-2506) Stroke Study Group. Safety and tolerability of arundic acid in acute ischemic stroke. J Neurol Sci 2006;251:50-6
22. Ginsberg MD. Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection: the 2002 Thomas Willis Lecture. Stroke 2003;34(11):214-23
23. Ginsberg MD, Hill MD, Palesch YY, et al. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke-I: Physiological responses and safety results. Stroke 2006;37:2100-6
24. Palesch YY, Hill MD, Ryckborst KJ, et al. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke-II: neurologic outcome and efficacy analysis. Stroke 2006;37:2107-14
25. Shin DH, Moon GJ, Bang OY. Albumin therapy in acute stroke patients. J Neurol 2007;254:870-8
26. Young RS, Zalneraitis EL, Dooling EC. Neurological outcome in cold water drowning. JAMA 1980;244:1233-5
27. Erecinska M, Thomsen M, Silver IA. Effects of hypothermia on energy metabolism in Mammalian central nervous system. J Cereb Blood Flow Metab 2003;23:513-30
28. Nakashima K, Todd MM. Effects of hypothermia on the rate of excitatory amino acid release after ischemic depolarization. Stroke 1996;27(15):913-8
29. Wang LM, Yan Y, Zou LJ, et al. Moderate hypothermia prevents neural cell apoptosis following spinal cord ischemia in rabbits. Cell Res 2005;15:387-93
30. Takata T, Nabetani M, Okada Y. Effects of hypothermia on the neuronal activity, [Ca2+]i accumulation and ATP levels during oxygen and/or glucose deprivation in hippocampal slices of guinea pigs. Neurosci Lett 1997;227:41-4
31. The Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurological outcome after cardiac arrest. N Engl J Med 2002;346:549-56
32. Zhi D, Zhang S, Lin W. Study on the therapeutic mechanism and clinical effect of mild hypothermia in patients with severe head injury. Surg Neurol 2003;59:381-5
33. Maier CM, Ahern K, Cheng MI, et al. Optimal depth and duration of mild hypothermia in a focal model of transient cerebral ischemia: effects on neurologic outcome, infarct size, apoptosis, and inflammation. Stroke 1998;29:2171-80
34. Dippel DW, van Breda EJ, van Gemert HM, et al. Effect of paracetamol (acetaminophen) on body temperature in acute ischemic stroke: a double-blind, randomized Phase II clinical trial. Stroke 2001;32:1607-12
35. De Georgia MA, Krieger DW, bou-Chebl A, et al. Cooling for Acute Ischemic Brain Damage (COOL AID): a feasibility trial of endovascular cooling. Neurology 2004;63:312-7
36. Mayer SA, Kowalski RG, Presciutti M, et al. Clinical trial of a novel surface cooling system for fever control in neurocritical care patients. Crit Care Med 2004;32:2508-15
37. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7
38. Kaste M, Hacke W, Fieschi C, et al. Results of the European Cooperative Acute Stroke Study (ECASS). Cerebrovasc Dis 1995;5:225
39. Hacke W, Kaste M, Fieschi C, et al. Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of trombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Lancet 1998;352:1245-51
40. Grond M, Stenzel C, Schmulling S, et al. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 1998;29:1544-9
41. Tanne D, Bates V, Verro P, et al. t-PA Stroke Survey Group. Initial experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. Neurology 1999;53:424-7
42. Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treament of acute stroke: the Standard Treatement with Alteplase to Reverse Stroke (STARS) study. JAMA 2000;283:1145-50
43. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischemic stroke in the Safe Implementation of Thrombolysis in Stroke Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369:275-82
44. Donnan GA, Hommel M, Davis SM, McNeil JJ. Steering committees for the ASK and MAST-E trials, Australasian streptokinase trial. Streptokinase in acute ischemic stroke. Lancet 1995;346:56
45. Multicentre Acute Stroke Trial-Italy (MAST_I) Group. Randomised controlled trial of streptokinase, aspirin and combination of both in treatment of acute ischemic stroke. Lancet 1995;346:1509-14
46. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatments: pooled analysis of ATLANTIS, ECASS and NINDS rt-PA stroke trials. Lancet 2004;363:768-74
47. Albers GW, Thijs VN, Wechsler L, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006;60:508-17
48. Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a Phase II MRI-based 9-hour window acute stroke thrombolysis trial wity intravenous desmoteplase. Stroke 2005;36:66-73
49. Lo EH, Broderick JP, Moskowitz MA. tPA and proteolysis in the neurovascular unit. Stroke 2004;35:354-6
50. Castellanos M, Leira R, Serena J, et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003;34:40-60
51. Castellanos M, Leira R, Serena J, et al. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 2004;35:1671-6
52. Daffertshofer M, Gass A, Ringleb P, et al. Transcranial low-frequency ultrasoundmediated thrombolysis in brain: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial. Stroke 2005;36:1441-6
53. Alexandrov AV, Molina CA, Grotta JC, et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004;351:2170-8
54. Molina CA, Ribo M, Rubiera M, et al. Microbubble administration accelerates clot lysis during continuous 2-mHz ultrasound monitoring in stroke patients created with intravenous tissue plasminogen activator. Stroke 2006;37:425-9
55. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. JAMA 1999;282:2003-11
56. Interventional Management of Stroke Investigators. The Interventional Management of Stroke (IMS) II Study. Stroke 2007;38:2127-35
57. Liu M, Counsell C, Zhao XL, Wardlaw J. Fibrinogen depleting agents for acute ischaemic stroke. Cochrane Database Syst Rev 2003;3:CD000091
58. Smith WS, Sung G, Starkman S, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results or the MERCY trial. Stroke 2005;36:1432-8
59. Feldman Z, Kanter MJ, Robertson CS, et al. Effect of head elevation on intracranial pressure, cerebral perfusion pressure, and cerebral blood flow in head-injured patients. J Neurosurg 1992;76:207-11
60. Meixensberger J, Baunach S, Amschler J, et al. Influence of body position on tissue-pO2, cerebral perfusion pressure and intracranial pressure in patients with acute brain injury. Neurol Res 1997;19:249-53
61. Schwarz S, Georgiadis D, Aschoff A, Schwab S. Effects of body position on intracranial pressure and cerebral perfusion in patients with large hemispheric stroke. Stroke 2002;33:497-501
62. Wojner-Alexander AW, Garami Z, Chernyshev OY, Alexandrov AV. Heads down: flat positioning improves blood flow velocity in acute ischemic stroke. Neurology 2005;64:1354-7
63. Schneider GH, von Helden GH, Franke R, et al. Influence of body position on jugular venous oxygen saturation, intracranial pressure and cerebral perfusion pressure. Acta Neurochir Suppl (Wien) 1993;59:107-12
64. Adams HP Jr. Emergent use of anticoagulation for treatment of patients with ischemic stroke. Stroke 2002;33:856-61
65. Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2001;119(Suppl 1):300S-320S
66. Camerlingo M, Salvi P, Belloni G, et al. Intravenous heparin started within the first 3 hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions. Stroke 2005;36:2415-20
67. Coull BM, Williams LS, Goldstein LB, et al. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Stroke 2002,33:1934-42
68. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 2006;113:e409-49
69. Einhaupl K, Bousser MG, de Bruijn SF, et al. EFNS guideline on the treatment of cerebral venous and sinus thrombosis. Eur J Neurol 2006;13(16):553-9
70. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1997;349:1569-81
71. CAST: randomised placebo-controlled. trial of early aspirin use in 20,000 patients with acute ischemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet 1997;349:1641-9
72. Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation 2002;105:1679-85
73. Larrue V, von Kummer RR, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001;32:438-41
74. Yusuf S, Zhao F, Mehta SR, et al. Effeces of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502
75. Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. The Abciximab in Ischemic Stroke Investigators. Stroke 2000;31:601-9
76. Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke 2005;36:880-90
77. Adams HP Jr, Effron MB, Torner J. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 2008;39:87-99
78. Amarenco P, Bogousslavsky J, Callahan A III, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-59
79. Sironi L, Cimino M, Guerrini U, et al. Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler Thromb Vasc Biol 2003;23:322-7
80. Kawashima S, Yamashita T, Miwa Y, et al. HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke 2003;34:157-63
81. Yoon SS, Dambrosia J, Chalela J, et al. Rising statin use and effect on ischemic stroke outcome. BMC Med 2004;2:4
82. Marti-Fabregas J, Gomis M, Arboix A. et al. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 2004;35:1117-21
83. Zhang L, Zhang ZG, Ding GL, et al. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation 2005;112:3486-94
84. Alvarez-Sabin J, Huertas R, Quintana M, et al. Prior statin use may be associated with improved stroke outcome after tissue plasminogen activator. Stroke 2007;38:1076-8
85. Powers WJ. Acute hypertension after stroke: the scientific basis for treatment decisions. Neurology 1993;43:461-7
86. Oliveira-Filho J, Silva SC, Trabuco CC, et al. Detrimental effect of blood pressure reduction in the first 24 hours of acute stroke onset. Neurology 2003;61:1047-51
87. Lisk DR, Grotta JC, Lamki LM, et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Arch Neurol 1993;50:855-62
88. Vlcek M, Schillinger M, Lang W, et al. Association between course of blood pressure within the first 24 hours and functional recovery after acute ischemic stroke. Ann Emerg Med 2003;42:619-26
89. Lisk DR, Grotta JC, Lamki LM, et al. Should hypertension be created after acute stroke? A randomized controlled trial using single photon emission computed tomography. Arch Neurol 1993;50:855-62
90. Fujii K, Weno BL, Baumbach GL, Heistad DD. Effect of antihypertensive treatment on focal cerebral infarction. Hypertension 1992;19:713-6
91. Schrader J, Luders S, Kulschewski A, et al. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003;34:1699-703
92. Davalos A, Cendra E, Teruel J, er al. Deteriorating ischemic stroke: risk factors and prognosis. Neurology 1990;40:1865-9
93. Langhorne P, Pollock A. What are the components of effective stroke unit care? Age Ageing 2002;31:365-71
94. Langhorne P. The main components of stroke unit care: what is the question? Cerebrovasc Dis 2007;23:464
95. Organised inpatient (stroke unit) care for stroke. Stroke Unit Trialists' Collaboration. Cochrane Database Syst Rev 2000;2:CD000197
96. Indredavik B, Bakke F, Slordahl SA, et al. Stroke unit treatment. 10-year follow-up. Stroke 1999;30:1524-7
97. Caplan LR. Cell therapy for stroke. NeuroRx 2004;1:406-14